- Home
- SEAT vs FHTX Comparison
SEAT vs FHTX Comparison
Compare SEAT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- FHTX
- Stock Information
- Founded
- SEAT 2001
- FHTX 2015
- Country
- SEAT United States
- FHTX United States
- Employees
- SEAT N/A
- FHTX N/A
- Industry
- SEAT Industrial Machinery/Components
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- SEAT Industrials
- FHTX Health Care
- Exchange
- SEAT Nasdaq
- FHTX Nasdaq
- Market Cap
- SEAT 465.6M
- FHTX 513.7M
- IPO Year
- SEAT N/A
- FHTX 2020
- Fundamental
- Price
- SEAT $3.52
- FHTX $7.84
- Analyst Decision
- SEAT Strong Buy
- FHTX Strong Buy
- Analyst Count
- SEAT 9
- FHTX 5
- Target Price
- SEAT $6.78
- FHTX $16.00
- AVG Volume (30 Days)
- SEAT 1.2M
- FHTX 122.0K
- Earning Date
- SEAT 11-07-2024
- FHTX 11-04-2024
- Dividend Yield
- SEAT N/A
- FHTX N/A
- EPS Growth
- SEAT N/A
- FHTX N/A
- EPS
- SEAT N/A
- FHTX N/A
- Revenue
- SEAT $774,076,000.00
- FHTX $25,515,000.00
- Revenue This Year
- SEAT $12.66
- FHTX N/A
- Revenue Next Year
- SEAT $6.00
- FHTX $8.77
- P/E Ratio
- SEAT N/A
- FHTX N/A
- Revenue Growth
- SEAT 13.91
- FHTX N/A
- 52 Week Low
- SEAT $3.33
- FHTX $2.70
- 52 Week High
- SEAT $8.80
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- SEAT 41.45
- FHTX 44.02
- Support Level
- SEAT $3.35
- FHTX $7.33
- Resistance Level
- SEAT $3.71
- FHTX $8.25
- Average True Range (ATR)
- SEAT 0.24
- FHTX 0.71
- MACD
- SEAT -0.03
- FHTX -0.13
- Stochastic Oscillator
- SEAT 21.31
- FHTX 21.52
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.